1990—2019年中国、日本、韩国胰腺癌流行病学趋势及主要风险归因分析

Epidemiological trends and major risk attribution analysis of pancreatic cancer in China, Japan and South Korea from 1990 to 2019

  • 摘要:
    目的 分析1990—2019年中国、日本、韩国胰腺癌流行病学趋势及主要风险归因。
    方法 应用描述性流行病学方法。收集1990—2019年全球疾病负担(GBD)数据库中中国、日本、韩国胰腺癌发病率、死亡率、年龄标准化发病率(ASIR)、年龄标准化死亡率(ASMR)。根据GBD数据库2019年全世界标准化人口结构计算年龄标准化率。观察指标:(1)2019年中国、日本、韩国胰腺癌发病和死亡情况。(2)1990—2019年中国、日本、韩国胰腺癌发病率和死亡率风险的年龄-时期-队列模型分析。(3)1990—2019年中国、日本、韩国胰腺癌ASIR和ASMR变化趋势。(4)1990—2019年中国、日本、韩国胰腺癌死亡主要风险归因变化趋势。计数资料以绝对数、百分率和比值表示。采用Joinpoint(V.4.7.0.0)软件回归计算不同时段胰腺癌发病率和死亡率的年变化率、年平均变化率(AAPC)及其95%可信区间(CI)。采用STATA(V.15.0)软件中年龄-时期-队列模型分析控制两个变量,不同年龄、时期和出生队列对胰腺癌发病和死亡风险的影响,风险效应值采用相对危险度(95%CI)表示。
    结果 (1)2019年中国、日本、韩国胰腺癌发病和死亡情况。2019年中国胰腺癌发病率从15~19岁的0.07/10万上升至85~89岁的64.01/10万,其中男性从0.09/10万上升至94.71/10万,女性从0.04/10万上升至47.47/10万;死亡率从0.04/10万上升至79.58/10万,其中男性从0.05/10万上升至116.50/10万,女性从0.03/10万上升至59.69/10万。日本胰腺癌发病率从15~19岁的0.03/10万上升至85~89岁的162.26/10万,其中男性从0.03/10万上升至177.67/10万,女性从0.04/10万上升至153.67/10万;死亡率从0.02/10万上升至154.88/10万,其中男性从0.02/10万上升至170.93/10万,女性从0.02/10万上升至145.94/10万。韩国胰腺癌发病率从15~19岁的0.04/10万上升至85~89岁136.78/10万,其中男性从0.03/10万上升至153.78/10万,女性从0.04/10万上升至129.73/10万;死亡率从0.02/10万上升至135.98/10万,其中男性从0.02/10万上升至156.21/10万,女性从0.02/10万上升至127.59/10万。中国胰腺癌人群发病和死亡人数高峰均出现在65~69岁男性群体,不同年龄组男性发病、死亡人数均高于同年龄组女性。日本胰腺癌人群发病人数高峰出现在80~84岁女性群体,死亡人数高峰出现在75~79岁男性群体,<80岁男性发病、死亡人数均高于同年龄组女性,≥80岁女性发病、死亡人数均高于同年龄组男性。韩国胰腺癌人群发病人数高峰出现在80~84岁女性群体,死亡人数高峰出现在70~74岁男性群体,<75岁男性发病、死亡人数均高于同年龄组女性,≥75岁女性发病、死亡人数均高于同年龄组男性。(2)1990—2019年中国、日本、韩国胰腺癌发病率和死亡率风险的年龄-时期-队列模型分析。年龄效应:矫正时期-队列效应,随着年龄的增长,中国、日本、韩国胰腺癌男性和女性发病率、死亡率风险均升高,其中女性较男性更明显,日本人群较中国、韩国人群更明显。时期效应:矫正年龄-队列效应,1990—2019年中国、日本、韩国胰腺癌男性和女性发病率、死亡率风险均呈上升趋势,其中中国人群时期效应更显著。队列效应:矫正年龄-时期效应,随着出生队列的推移,中国、日本、韩国胰腺癌男性和女性发病率、死亡率风险均降低。(3)1990—2019年中国、日本、韩国胰腺癌ASIR和ASMR变化趋势。1990—2019年中国胰腺癌ASIR、ASMR均呈逐年上升趋势,2019年ASIR、ASMR分别为1990年的1.82倍、1.79倍。日本胰腺癌ASIR、ASMR均呈缓慢上升趋势,2019年ASIR、ASMR分别为1990年的1.09倍、1.05倍。韩国胰腺癌ASIR、ASMR均呈先上升后下降再缓慢上升趋势。1990—2019年中国胰腺癌ASIR的AAPC为2.08%(95%CI为1.91%~2.24%,P<0.05);ASMR的AAPC为2.02%(95%CI为1.86%~2.19%,P<0.05)。日本胰腺癌ASIR的AAPC为0.28%(95%CI为0.15%~0.42%,P<0.05);ASMR的AAPC为0.13%(95%CI为0.03%~0.24%,P<0.05)。韩国胰腺癌ASIR的AAPC为0.50%(95%CI为0.21%~0.80%,P<0.05);ASMR的AAPC为0.15%(95%CI为-0.10%~0.40%,P>0.05)。(4)1990—2019年中国、日本、韩国胰腺癌死亡主要风险归因变化趋势。1990—2019年中国、日本、韩国胰腺癌死亡主要风险归因依次为吸烟、高空腹血糖和高体质量指数(BMI)。主要风险归因为吸烟的胰腺癌死亡占比趋势显示:中国男性由1990年的31.4%上升至2000年的34.1%,继下降至2015年的31.1%,后呈缓慢上升趋势至2019年的31.7%;女性由1990年的6.7%上升至2005年的10.4%,继下降至2019年的8.7%。日本男性由1990年的38.8%下降至2019年的26.9%;女性由1990年的20.9%下降至2019年的14.8%。韩国男性由1990年的37.5%下降至2019年的30.3%;女性由1990年的12.6%下降至2019年的10.0%。主要风险归因为高空腹血糖的胰腺癌死亡占比趋势显示:中国男性由1990年的5.9%上升至2019年的7.1%;女性由1990年的6.2%上升至2019年的6.8%。日本男性由1990年的7.0%上升至2019年的7.7%;女性由1990年的5.0%上升至2019年的5.5%。韩国男性由1990年的6.8%上升至2019年的9.7%;女性由1990年的6.1%上升至2019年的8.2%。主要风险归因为高BMI的胰腺癌死亡占比趋势显示:中国男性由1990年的1.3%上升至2019年的3.0%;女性由1990年的2.1%上升至2019年的4.3%。日本男性由1990年的2.0%上升至2019年的2.4%;女性由1990年的3.1%上升至2019年的3.4%。韩国男性由1990年的1.9%上升至2019年的3.1%;女性由1990年的3.4%上升至2019年的4.3%。
    结论 中国胰腺癌发病率仍然处于持续上升状态,日本和韩国趋于稳定。女性尤其是老年女性的胰腺癌发病状况更需要得到关注。吸烟仍是最需要重视的胰腺癌危险因素;同时应更加关注高空腹血糖和高BMI增加罹患胰腺癌风险。

     

    Abstract:
    Objective To analyze the epidemiological trends and major risk attribution of pancreatic cancer in China, Japan and South Korea from 1990 to 2019.
    Methods The descriptive epidemiological method was conducted. The overall incidence rate, mortality rate, age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of pancreatic cancer in China, Japan and South Korea from 1990 to 2019 were collected from the Global Burden of Disease (GBD) Database. Age-standardized rates were calculated based on the worldwide standardized population structure provided by GBD Database 2019. Observation indicators: (1) incidence and motality of pancreatic cancer in China, Japan and South Korea in 2019; (2) age-period-cohort model analysis of incidence and mortality rates of pancreatic cancer in China, Japan and South Korea from 1990 to 2019; (3) trends of ASIR and ASMR of pancreatic cancer in China, Japan and South Korea from 1990 to 2019; (4) trends of major risk attribution of pancreatic cancer related death in China, Japan and South Korea from 1990 to 2019. Count data were represented as absolute numbers, percentages and ratios. Joinpoint V.4.7.0.0 software was used to calculate the annual percentage change (APC), the average annual percentage change (AAPC) of incidence and mortality rates of pancreatic cancer in different time periods and 95% confidence interval (95%CI). The age-period-cohort model in STATA V.15.0 software was used to analyze the influence of different ages, periods and birth cohorts on the risk of onset and death of pancreatic cancer after controlling the other two variables, with the risk effect size described as relative risk (95%CI).
    Results (1) Incidence and motality of pancreatic cancer in China, Japan and South Korea in 2019. In 2019, the incidence rate of pancreatic cancer in China increased from 0.07/100,000 among 15-19 years old to 64.01/100,000 among 85-89 years old, with increasing from 0.09/100,000 to 94.71/100,000 in males and from 0.04/100,000 to 47.47/100,000 in females. The mortality rate of pancreatic cancer in China increased from 0.04/100,000 among 15-19 years old to 79.58/100,000 among 85-89 years old, with increasing from 0.05/100,000 to 116.50/100,000 in males and from 0.03/100,000 to 59.69/100,000 in females. The incidence rate of pancreatic cancer in Japan increased from 0.03/100,000 among 15-19 years old to 162.26/100,000 among 85-89 years old, with increasing from 0.03/100,000 to 177.67/100,000 in males and from 0.04/100,000 to 153.67/100,000 in females. The mortality rate of pancreatic cancer in Japan increased from 0.02/100,000 among 15-19 years old to 154.88/100,000 among 85-89 years old, with increasing from 0.02/100,000 to 170.93/100,000 in males and from 0.02/100,000 to 145.94/100,000 in females. The incidence rate of pancreatic cancer in South Korea increased from 0.04/100,000 among 15-19 years old to 136.78/100,000 among 85-89 years old, with increasing from 0.03/100,000 to 153.78/100,000 in males and from 0.04/100,000 to 129.73/100,000 in females. The mortality rate of pancreatic cancer in South Korea increased from 0.02/100,000 among 15-19 years old to 135.98/100,000 among 85-89 years old, with increasing from 0.02/100,000 to 156.21/100,000 in males and from 0.02/100,000 to 127.59/100,000 in females. The peak incidence and mortality of pancreatic cancer in China were found in males aged 65-69 years, and the overall incidence and mortality of males in different age groups were higher than those of females in the same age group. In Japan, the peak incidence of pancreatic cancer occurred in females aged 80-84 years and the peak mortality occurred in males aged 75-79 years. The morbidity and mortality of males aged <80 years were higher than those of females in the same age group, while the morbidity and mortality of males aged ≥80 years were lower than those of females in the same age group. In South Korea, the peak incidence of pancreatic cancer occurred in females aged 80-84 years, and the peak mortality occurred in males aged 70-74 years. The morbidity and mortality of males aged <75 years were higher than those of females in the same age group, while the morbidity and mortality of males aged ≥75 years were lower than those of females in the same age group. (2) Age-period-cohort model analysis of incidence and mortality rates of pancreatic cancer in China, Japan and South Korea from 1990 to 2019. Age effect: after adjustment for the period and cohort effects, the risk of incidence and mortality rates of pancreatic cancer in both males and females of China, Japan and South Korea increased with age, which is more obvious in females than males, and more obvious in Japanese than Chinese and Korean populations. Period effect: after adjustment for age and cohort effects, the risk of incidence and mortality rates of pancreatic cancer in both males and females of China, Japan and South Korea increased from 1990 to 2019, with the period effect more significant in the Chinese population. Cohort effect: after adjustment for age and period effects, the risk of morbidity and mortality rates of pancreatic cancer decreased with the passage of birth cohort in China, Japan and South Korea. (3) Trends of ASIR and ASMR of pancreatic cancer in China, Japan and South Korea from 1990 to 2019. The ASIR and ASMR of pancreatic cancer in China increased yearly from 1990 to 2019, and the ASIR and ASMR in 2019 were 1.82 times and 1.79 times those in 1990, respectively. The ASIR and ASMR of pancreatic cancer in Japan showed a slowly increasing trend, and the ASIR and ASMR in 2019 were 1.09 times and 1.05 times those in 1990, respectively. The ASIR and ASMR of pancreatic cancer in South Korea increased firstly, then decreased, and slowly increased. From 1990 to 2019, the AAPC of ASIR of pancreatic cancer in China was 2.08% (95%CI as 1.91% to 2.24%, P<0.05) and AAPC of ASMR was 2.02% (95%CI as 1.86% to 2.19%, P<0.05). The AAPC of ASIR of pancreatic cancer in Japan was 0.28% (95%CI as 0.15% to 0.42%, P<0.05) and AAPC of ASMR was 0.13% (95%CI as 0.03% to 0.24%, P<0.05). The AAPC of ASIR of pancreatic cancer in South Korea was 0.50% (95%CI as 0.21% to 0.80%, P<0.05) and AAPC of ASMR was 0.15% (95%CI as -0.10% to 0.40%, P>0.05). (4) Trends of major risk attribution of pancreatic cancer related death in China, Japan and South Korea from 1990 to 2019. The main risk factors for pancreatic cancer related death in China, Japan and South Korea from 1990 to 2019 were smoking, high fasting glucose and high body mass index (BMI). The trend of pancreatic cancer related death, mainly attributed to smoking, showed that the proportion of Chinese males increased from 31.4% in 1990 to 34.1% in 2000, then decreased to 31.1% in 2015, and then showed a slow increase to 31.7% in 2019. The proportion of Chinese females increased from 6.7% in 1990 to 10.4% in 2005 and then dropped to 8.7% in 2019. The proportion of Japanese males decreased from 38.8% in 1990 to 26.9% in 2019 and the proportion of Japanese females decreased from 20.9% in 1990 to 14.8% in 2019. The proportion of South Korean males decreased from 37.5% in 1990 to 30.3% in 2019 and the proportion of South Korean females decreased from 12.6% in 1990 to 10.0% in 2019. The trend of pancreatic cancer related death proportion, mainly attributed to high fasting blood glucose, showed that the proportion of Chinese males increased from 5.9% in 1990 to 7.1% in 2019 and the propor-tion of Chinese females increased from 6.2% in 1990 to 6.8% in 2019. The proportion of Japanese males increased from 7.0% in 1990 to 7.7% in 2019 and the proportion of females increased from 5.0% in 1990 to 5.5% in 2019. The proportion of South Korean males increased from 6.8% in 1990 to 9.7% in 2019 and the proportion of females increased from 6.1% in 1990 to 8.2% in 2019. The trend of pancreatic cancer related deaths proportion, attributed mainly to high BMI, showed that the proportion of Chinese males increased from 1.3% in 1990 to 3.0% in 2019 and the proportion of females increased from 2.1% in 1990 to 4.3% in 2019. The proportion of Japanese males increased from 2.0% in 1990 to 2.4% in 2019 and the proportion of females increased from 3.1% in 1990 to 3.4% in 2019. The proportion of South Korean males increased from 1.9% in 1990 to 3.1% in 2019 and the proportion of females increased from 3.4% in 1990 to 4.3% in 2019.
    Conclusions The incidence of pancreatic cancer in China may continue to rise but to be stable in Japan and South Korea. The incidence of pancreatic cancer in females, especially elderly women, needs more attention. Smoking remains the most critical risk factor for pancreatic cancer. More attention should also be paid to the increased risk of pancreatic cancer associated with high BMI and high fasting plasma glucose.

     

/

返回文章
返回